Transformative effect of a Humanitarian Program for individuals affected by rare diseases: building support systems and creating local expertise

I. C. Verma¹, A. El-Beshlawy², A. Tylik-Szymańska³, A. Martins⁴, Y.-L. Duan⁵, T. Collin-Histed⁷, M. Schoneveld van der Linde⁸, R. Mansour⁹, V. C. Dũng¹⁰ and Pramod K. Mistry¹¹*

Abstract

Rare diseases affect > 400 million people globally with a disproportionate burden falling on children, resulting in high morbidity and mortality rates. Affected individuals in some under-resourced countries have limited access to expert care or treatments; moreover, they suffer long diagnostic journeys during which debilitating and life-threatening complications occur. Lysosomal storage disorders (LSD) are prototype rare diseases due, in the main, to inherited deficiencies of lysosomal enzymes/transporters that affect up to 1 in 5000 newborns. Recognizing the need to provide treatment access to people with LSDs everywhere, a collaborative partnership was pioneered and set up 30 years ago. Partnering with local authorities, non-government organizations across six continents, local as well as international experts, a robust, sustainable Humanitarian Program emerged that now represents the most enduring charitable access program for LSD treatment. Here we present the history, process, lasting beneficial effect of the program to develop healthcare systems and infrastructures, and the lessons learned from addressing major unmet needs for LSDs.

Keywords: Humanitarian Program, Charitable program, Rare diseases, Lysosomal storage disorders, Enzyme replacement therapy

Background

Rare diseases affect > 400 million people globally, impacting more individuals than cancer and acquired immune deficiency syndrome (AIDS) combined [1]. These individuals have little or no access to healthcare and undergo protracted diagnostic journeys, enduring chronic disability and life-threatening complications [2], while being vulnerable to stigma and local cultural prejudices. In some regions, a disproportionate burden of disease falls on the children of resource-poor populations, resulting in high morbidity and premature mortality [1].

Lysosomal storage disorders (LSDs) are prototype rare diseases that are, for the most part, due to deficiencies in one of the lysosomal enzymes/transporters [3, 4], with a combined incidence of up to 1 in 5000 newborns [5]. The accumulation of toxic substrates in the lysosomes results in cellular dysfunction, multisystem organ damage, and heterogeneous disease manifestations in children and adults (Table 1) [3, 4].

Although recombinant enzyme replacement therapies (ERT) are available for increasing numbers of these disorders, it is challenging for affected individuals in under-served populations to access treatment due to...
Table 1  Clinical manifestations of selected lysosomal storage disorders [3, 4]

| Disease             | Subtypes                                | Gene   | Treatment                      | Enzyme                | Substrate            | Clinical manifestations                                  |
|---------------------|-----------------------------------------|--------|--------------------------------|-----------------------|----------------------|---------------------------------------------------------|
| Gaucher disease     | Three clinical phenotypes:              |        |                                |                       |                      |                                                         |
|                     | Type I, which does not have neurologic involvement | GBA    | Imiglucerase— (Gaucher disease type I and type III) | Glucocerebrosidase   | Glucosylceramide     | Hepatosplenomegaly, thrombocytopenia, anemia, bone pain, and poor growth in children |
|                     | Types II and III, the so-called neuronopathic forms, which both feature neurologic impairment |        | Alglucerase— (Gaucher disease type I) |                       |                      |
|                     | Eliglustat tetratate— (Gaucher disease type I) |        |                                |                       |                      |
| Fabry disease       | Age of onset is highly variable and can range from early childhood to the fifth decade or later | GLA    | Agalsidase beta                | Alpha-galactosidase A/Alpha-galactosidase | Globotriaosylceramide (GL3) | Neuropathic pain, gastrointestinal symptoms, angokeratomas (clusters of purplish, non-blanching punctate lesions) and hypohidrosis, and deteriorating renal function |
| Pompe disease       | Infantile onset Pompe disease           | GAA    | Alglucosidase e alfa           | Alglucosidase e alfa | Glycogen              | Hypertrophic cardiomyopathy, respiratory insufficiency, respiratory failure, muscle weakness, feeding/swallowing difficulties, hypotonia, and developmental delay |
|                     | Late onset Pompe disease                |        |                                |                       |                      | Limb-girdle weakness, respiratory insufficiency, feeding/swallowing difficulties, gastrointestinal symptoms, ptosis |
| MPS I               | Seven distinct forms (I, II, III, IV, VI, VII, IX) and numerous subtypes (eg, IIIA, IIIB, IIIC, IIID) | MPS I: IDUA | Laronidase                     | Alpha-L-iduronidase   | Mucopolysaccharides (eg, dermatan sulfate, heparan sulfate, keratan sulfate) | Developmental delay, organomegaly, and dysostosis multiplex |
|                     | MPS II: IDS                             |        |                                |                       |                      |                                                         |
|                     | MPS VI: ARSB                            |        |                                |                       |                      |                                                         |

ARSB, arylsulfatase B precursor; GAA, acid alpha-glucosidase; GBA, glucocerebrosidase; GLA, galactosidase alpha; IDUA, alpha-L-iduronidase; MPS, mucopolysaccharidosis
Thirty years ago, a collaborative Humanitarian Program was pioneered by Genzyme (now Sanofi Genzyme) (Fig. 1) based on the premise that individuals with LSDs should have access to treatment regardless of circumstance. This mission was fulfilled through the pioneering of a robust, sustainable Humanitarian Program in partnership with local authorities and non-government organizations (NGO) across six continents [7]. To date, the program has provided treatment for >3300 individuals in more than 100 countries, some of whom have received treatment for >20 years (Fig. 2) for the LSDs Gaucher disease (GD), Fabry disease (FD), Pompe disease (PD), and mucopolysaccharidosis (MPS) type I and II (Table 2).

The Humanitarian Program is the longest-running charitable access program (CAP) for treatment of LSDs providing sustainable global access to therapies for affected people, regardless of local healthcare system infrastructures [8]. To address the global unmet need in devastating LSDs, a new model was required, distinct from existing programs, such as those for neglected tropical diseases [8, 9]. This new model also helped develop local clinical expertise and infrastructure for diagnosis, disease monitoring, and logistics.

The program was initiated in the United States (US) in 1991 through the launch of the CAP within 3 months of alglucerase (Ceredase®) approval, the first ERT for GD type 1 [10, 11]. Individuals were accepted for compassionate treatment on a case-by-case basis, and it rapidly became apparent that a regionally focused healthcare infrastructure within countries was necessary for these rare diseases due to distinct presentations, novel phenotypes, and genotypes. Multiple regional initiatives were rolled out, culminating in the first non-US collaboration with an NGO (the Gaucher Initiative/Project HOPE [Health Opportunities for People Everywhere]). Herein, we highlight the history, process, the lasting impact of this program, and its positive effect on healthcare systems and improved infrastructure to help identify, diagnose, and manage individuals with LSDs. Specific examples of the successful program implementation are illustrated by reference to GD, but parallel initiatives for other LSDs have been established.

To assess current perceptions of the program’s impact and challenges, information was collected through a series of qualitative web-based interviews with key individuals instrumental in the program roll-out and evolution. An online survey was also conducted to evaluate operational aspects (e.g., length of participation, number of individuals treated, and disruptions to
treatment), experience of the program, and suggestions for improvement. The survey was open to 320 physicians with experience in treating LSDs across 70 countries. The privacy and personal data of respondents were protected in accordance with the applicable laws and terms of Global Sanofi Privacy Policy. The insights gathered and reported herein represent the collective experience of > 50,000 patient-years of treating LSDs, spanning up to 40 years, and decades-long leadership in rare-disease patient advocacy.

**Results**

**Major learnings**

Successful program implementation requires an infrastructure supporting treatment access, coupled with concurrent development of healthcare ecosystems. Central
to this are education, development of diagnostic technologies, disease monitoring, and building of expertise in local centers to eventually develop into destination centers where individuals with LSDs can receive diagnosis, therapy and monitoring of outcomes. Success was underpinned by striving to meet the needs of all stakeholders involving seamless partnership with members of the local treating communities, patient advocacy groups and organizations, and the healthcare system. Healthcare delivery for LSDs begins with a compassionate case-by-case response at the country level reaching far beyond simply shipping the drug. At its earliest beginnings Sanofi Genzyme recognized the essential need to build skill sets and infrastructure to support complex care for these people. Individual physician training rapidly evolved into medical advisory boards of enterprising local physicians, international expert physicians, and humanitarian initiative staff. These forums served as platforms for training and mentorship by international leaders, such that over time local physicians became thought leaders advancing the science and generating new knowledge in these rare diseases. The medical advisory boards collaboratively developed treatment guidelines, monitoring, and stratification of individuals based on disease pattern, severity, and genotypes. Over time, local expert physicians took increasing leadership in individuals’ selection, considering nuances of disease phenotypes, and treatment plans. Often, the phenotypes encountered had no prior counterpart in world literature, which is primarily European-centric. Technological developments included logistics of cold-chain transport of medication, advanced assessments to monitor the individuals, and transfer of knowledge and capabilities from a country with limited resources to a central laboratory in another country. For example, the development of dry-blood-spot technology for biochemical molecular analysis, and biomarkers studies in LSDs, advanced monitoring of individuals in remote locations without the need to ship whole blood samples to specialist laboratories. Partnership with rare-disease patient advocates and advocacy groups, renowned for their disease knowledge, was invaluable in ensuring free access to additional medical devices. Creation of such comprehensive healthcare systems supported by skilled providers is critical for improving the health of people with LSDs, and providing an established functional framework to elevate advocacy with local authorities to address the huge unmet needs of this underserved population. Achievement of these goals required overcoming disparate cultural, social, trade policy and political barriers.

**Infrastructure and standard operating procedures**

From its inception, the governance structure has ensured the program remains compliant with ethical standards, institutional policies, and external governmental requirements, and continues to meet the strategic goals and the foundational mission of the Humanitarian Program (Fig. 3). It operates under the guidance of independent

---

**The following guiding principles convey the core values and philosophical framework of the Humanitarian Program and assist in program-related decision making:**

- The Humanitarian Program is a vital element of Sanofi Genzyme’s mission to develop sustainable healthcare systems and improve patient outcomes.
- Sanofi Genzyme aspires to create sustainable access to therapy for patients enrolled in the Humanitarian Program, yet it understands this can take time; Sanofi Genzyme’s commitment to patients enrolled in the Humanitarian Program is long term.
- Sanofi Genzyme will give patients enrolled in the Humanitarian Program the same treatment and attention as patients who receive product outside the Humanitarian Program. Patients in the Humanitarian Program are eligible for entry into the Sanofi Genzyme Registries.
- The Humanitarian Program will strive for operational excellence and will comply with local and global regulations and laws.
- The Humanitarian Program is intended to aid countries in establishing an infrastructure to support patient care for the long term; local Sanofi Genzyme teams have the responsibility to partner with local governments and physicians as a part of this initiative.
- The primary goal of the Humanitarian Program is to deliver therapies, to the best of Sanofi Genzyme’s ability, to LSD patients with a demonstrated need in certain circumstances where treatment access is limited.
- Treatment through the Humanitarian Program is provided only when recommended by a patient’s local treating physician and is based on medical need. Medical need is determined by consistent criteria related to the body of evidence of best practices in disease management, including factors such as (a) knowledge about treatment response and (b) product indication and labeling.
- All programs operated under the Humanitarian Program (country-specific programs included) will be managed under these Guiding Principles. Sanofi Genzyme will strive for global, umbrella programs where possible.
medical review boards, whose composition is region-dependent; for instance, the expert medical committee for the Gaucher Initiative comprises leading experts in GD, staff from Project HOPE and Sanofi Genzyme, and a medical ethicist [8].

Prioritization of individuals or countries is driven by the individuals’ need and is agnostic to the likelihood of government reimbursement or competitive market forces. Candidacy for treatment is primarily based on medical need in the following circumstances: when reimbursement is unavailable, until reimbursement is available, when reimbursement is available but the individual does not qualify, and when other local access or assistance programs are unavailable.

The governance structure was tailored to individual country requirements to best serve that population (Fig. 1). For example, in Egypt, as most people with GD present with massive visceral and hematologic disease in childhood, the medical advisory board had a preponderance of pediatricians and pediatric hematologists.

**Physicians’ perspectives**

To evaluate the program and solicit opinions on future enhancements, 320 physicians with experience of treating LSDs were invited to take part in an online survey. Overall, 114 respondents from 42 countries completed the survey, of which 63% of physicians had individuals currently enrolled in the program. Respondents represented a broad range of specialties, including geneticists (27%), pediatricians (21%), and neurologists (13%; Fig. 4A).

Over 92% of physicians became aware of the Humanitarian Program through local or regional medical Sanofi Genzyme contacts (Fig. 4B). Two-thirds of physicians had up to five individuals that had participated in the
program, with some physicians having over 20. A third (34%) of physicians reported that it took <6 months following confirmed diagnosis for individuals to start receiving treatment, with half (54%) of all physicians reporting receiving treatments within 1 year; treatment disruptions due to COVID-19 (a lack of safe areas for infusion, country lockdowns, and travel restrictions) were noted by 35% of physicians.

Most physicians (94%) reported that individuals under their care received the scheduled treatment regularly. The remaining 6% reported challenges to treatment access, including: government regulations, challenges with storage logistics, individuals unable to comply with all the monitoring guidelines, limited financial resources for logistics of getting infusion treatment/challenging environment, delays in receiving medication, and challenges in contacting individuals.

Most physicians (92%) reported that they did not experience any problems when completing the required application forms or providing medical updates every 6 months, however, some suggestions for improvements to the program included digitizing the enrollment process, reducing the ongoing paperwork, and improving disease awareness and support.

**Examples of successful implementation**

Country-specific examples of the successful implementation to build healthcare infrastructure serving LSDs in underserved populations illustrate how, the entire clinical spectrum of GD, for example, has been redefined to serve the individual's unique needs. Figure 5 depicts examples of individuals with LSDs who have benefited from the program. Cases 1, 2, and 4–6 show the common phenotypes of severe hepatosplenomegaly and failure to thrive pre-ERT due to GD, and resolution post-ERT. Case 3 shows infantile onset of PD with reversal of cardiomyopathy post-ERT. Of note, in some cases the benefit has extended further to the individuals’ siblings, enabling their early diagnoses and treatment.

**Egypt**

The numbers of individuals with GD needing medical care became immediately evident upon inception of the program in 1999, when the number of individuals grew from 12 to 37. Project HOPE was a key partner, raising awareness of GD and assessing the gaps in treatment access. It was considered the most effective partner to manage the Gaucher Initiative, having operated in Egypt since 1975, and collaborating with the Ministry of Health and University Hospitals across the country for other healthcare initiatives. This collaboration with Project HOPE was critical in implementing many aspects of the program, including annual training for Egyptian doctors via international and national experts, and patient and family awareness activities. This initiative robustly models the key pillars of building healthcare systems, starting with affected individuals and their families, mentorship, and development of thought leaders within medical committees to achieve high-level expertise on how best to evaluate candidacy for treatment, assessing outcomes, and contributing gained knowledge to benefit the global community. To date, the program has supported >250 individuals in Egypt with GD treated at centers of excellence established across the county, obviating the need to travel long distances for diagnosis, evaluation, and treatment.

**India**

Initiated 20 years ago, the program in India has supported >200 individuals across four LSDs. The program has resulted in improved awareness, diagnosis, and management of individuals with LSDs through the development of several centers of excellence and diagnostic capabilities, along with the implementation of medical-education initiatives for individuals with GD, FD, and PD [12–15]. Local physicians who had experience in inborn errors of metabolism expedited the rapid configuration and operation of the India Medical Advisory Board, which comprises of these experts and a group of international practitioners, chosen for their specialist knowledge of LSDs, culturally sensitive ethical considerations, and understanding of the local healthcare system. Medical educational activities and workshops played an important role in upskilling physicians caring for individuals with LSDs. There is now a cadre of expert physicians in India who are contributing new knowledge to the field.

**China**

The China CAP has grown to support >180 individuals with GD since its initiation in 1999. Since 2009, centers have spread across China, providing accurate diagnostic support and treatment for LSDs, and obviating the need to travel long distances. A growing number of provinces contribute toward costs through government medical insurance. The program’s flexibility allows for partial humanitarian support for >50 individuals. The expert medical committee in China has developed treatment guidelines and provided country-wide clinical expertise.

**Central and Eastern Europe**

Since the late 1990s individuals severely affected with GD unable to receive treatment in Central and Eastern Europe have been treated via the Humanitarian Program. Individual European countries such as Albania, Belarus, Bosnia, North Macedonia and Serbia, rapidly adopted management of individuals with LSDs, propelled by
powerful advocacy groups, which has transformed care. Early access to treatment in these countries has advanced physicians’ knowledge, shortening diagnostic journeys, and improving treatment outcomes.

**Global impact**
The impact on the lives of individuals with LSDs has been transformative. Thus far, the Humanitarian Program has provided treatment to >3300 individuals across more than 100 countries, some for over 20 years, with the average treatment duration ranging from 3 years (for MPS type II) to 9.8 years (for GD; Fig. 6). There are currently >1000 individuals active in the program as of May 2021, with 156 individuals initiating treatment in 2020 alone. The program has also successfully allowed individuals to become disease advocates helping to increase awareness. Examples of the cascade effect of the program are demonstrated by the formations of the Organization for Rare Diseases India (ORDI), by a father of an individual with PD treated in the program in India, and the Philippine Society for...
Orphan Disorders (PSOD), by another individual with PD and his family in the Philippines (Fig. 7).

Experienced members of advisory boards have also played a pivotal role, with overseas experts mentoring local physicians in all aspects of LSDs. This mentorship has been central to the program, with local physicians emerging as experts contributing new knowledge to benefit the rest of the world [14, 15]; local physician communities have become highly knowledgeable in rare diseases, shortening diagnostic odysseys, and allowing for maximum clinical impact of ERT.

Resilience and guiding principles for the Humanitarian Program in times of crisis

Operating a program of this magnitude and global reach is challenging. The lessons learned and the measures implemented to overcome obstacles at the local and global level are key to ensuring the resilience of the program.

A hallmark of the program is providing access to treatment for affected individuals who meet the medical criteria, regardless of geography. This includes sanctioned markets such as Cuba, Iran, and Sudan, where treatment access has been provided through the program for 20 years. Other examples include supporting individuals with rare diseases in Palestine, and those displaced due to war or conflict in their countries of origin, for eg, Syrian and Iraqi refugees living in Turkey. In some of these geographies, the program enlists the help of NGO partners to ensure long-term therapy and overcome barriers to treatment access. The ethical underpinnings of the program were tested during a global supply shortage of agalsidase beta in 2009 and imiglucerase in 2010 that required dose-conservation guidelines to be implemented. However, doses were rationed equitably among the most critically affected individuals and Humanitarian Program recipients to ensure that the reduced product supply was distributed based solely on medical need [16].

One of the current challenges faced by the program is the COVID-19 pandemic, which has resulted in altered relationships between international and local humanitarian organizations, deepening inequalities in access to service and the need to find creative solutions for providing access to treatment for individuals with rare disease. Nonetheless, the resiliency of the program is evident in continued treatment of affected people without interruption. Other challenges, with potential solutions, are outlined in Table 3.

Reflection and vision for the future

The Humanitarian Program is an exemplar of the rare-disease community coalescing with Sanofi Genzyme’s core mission to serve one person at a time, for individuals everywhere [17]. It started as a bold vision to provide treatment access, help build sustainable healthcare systems, and improve the lives of people with LSDs. Over 3 decades it has evolved and, despite facing challenges and an ever-changing landscape, has remained true to its mission. The program has increased awareness and skills in managing LSDs, shortened diagnostics journeys, and provided treatment access, giving individuals with rare diseases the opportunity to enjoy

Fig. 6 Percentage of individuals currently receiving enzyme replacement therapy in the program by time on treatment. Data as of May 2021. Note: humanitarian access to MPS II is limited to Sanofi Genzyme territory only. MPS, mucopolysaccharidosis
healthier lives. Importantly, the evolution of humanitarian programs and transformation of lives has generally led to the development of interest and expertise in managing individuals affected by other rare diseases. The program has also highlighted the importance of cultural practices. For example, in India, where populations with rare diseases are not a healthcare priority, the disproportionate disease burden borne by these individuals is further compounded by consanguineous marriages. This has necessitated the introduction of culturally sensitive genetic counseling, which has been embraced by these populations, and reduced the risk of disease in offspring.

Fig. 7 Examples of individuals with rare diseases enrolled into Humanitarian Program realizing their potential
| Challenges                                                                 | Solutions                                                                                                           |
|---------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------|
| Infrastructure                                                              | Involve all stakeholders, including external partners (individuals with rare diseases, physicians, government, patient association groups, and NGOs) and internal team members at global, regional, and local level. Facilitate diagnostic services by utilizing global and regional networks in countries where local testing is not available. Engage with a respected NGO with a strong local presence to help facilitate development of in-country capacities. Create expert medical committees to increase local knowledge and understanding of disease awareness, diagnosis, treatment benefit, and follow-up. |
| Lack of infrastructure for diagnosis, treatment, and management of individuals with LSDs. Availability of specialists in treatment of LSDs and treatment centers. | Involve all stakeholders, including external partners (individuals with rare diseases, physicians, government, patient association groups, and NGOs) and internal team members at global, regional, and local level. Facilitate diagnostic services by utilizing global and regional networks in countries where local testing is not available. Engage with a respected NGO with a strong local presence to help facilitate development of in-country capacities. Create expert medical committees to increase local knowledge and understanding of disease awareness, diagnosis, treatment benefit, and follow-up. |
| Medical expertise                                                          | Require ongoing training and education for healthcare providers to raise awareness of LSDs, support accurate diagnosis, assist with treatment access, knowledge of treatment administration, and disease management. Create a sustainable ecosystem for individual care within a given country. Create centers of excellence and referral hospitals to facilitate proper diagnosis and initiation of treatment. Provide local expertise and enhance relationships that help support individuals and navigate the challenges that may be involved in reaching them. |
| Order processing and shipment logistical delays                            | Partnerships with other humanitarian and patient organizations globally. Coordinate with NGOs in order to obtain import permits, tax waivers, and to better understand bureaucratic obstacles. Integrate Humanitarian Program activity into all business processes, including demand forecasting, supply planning, shipping, and trade compliance. Find creative solutions to ensure uninterrupted treatment for individuals (eg, delivery via road rather than air, cargo reallocation of product between hospitals, higher shipment quantity to reduce number of shipments); critical during COVID-19 pandemic and times of country crisis. |
| Extensive delays incurred due to the need for advanced provision of extensive documentation and bureaucratic challenges, for example, obtaining import permits. Navigating local financial bureaucracy around donations, including import taxes, duty regulations, and cost exemptions. Additional lead time needed for testing, release, shipping, and packaging products in view of cold-chain considerations. During the COVID-19 pandemic, many countries closed their borders, thereby disrupting the medication supply for many individuals. | Partnerships with other humanitarian and patient organizations globally. Coordinate with NGOs in order to obtain import permits, tax waivers, and to better understand bureaucratic obstacles. Integrate Humanitarian Program activity into all business processes, including demand forecasting, supply planning, shipping, and trade compliance. Find creative solutions to ensure uninterrupted treatment for individuals (eg, delivery via road rather than air, cargo reallocation of product between hospitals, higher shipment quantity to reduce number of shipments); critical during COVID-19 pandemic and times of country crisis. |
| The need to work with local government, healthcare providers, and key stakeholders to establish sustainable healthcare services for individuals with LSDs that are compliant to local regulatory and/or government requirements from diagnosis through treatment administration and follow-up. | Involve all stakeholders, including external (patients, physicians, government, patient association groups) and internal team members at a global, regional, and local level. |
| Program sustainability and unmet needs                                    | Active commitment and engagement from company leadership Engage with all local stakeholders and clearly communicate the program benefits and requirements Listen to the rare-disease community, recognize that there are unmet needs, and continue to evaluate program product offerings and criteria. |
| Ensuring program is sustainable                                            | Active commitment and engagement from company leadership Engage with all local stakeholders and clearly communicate the program benefits and requirements Listen to the rare-disease community, recognize that there are unmet needs, and continue to evaluate program product offerings and criteria. |
| Addressing unmet needs to specific populations due to program limitations (eg, lack of treatment access for newly diagnosed adults with Gaucher disease). | Active commitment and engagement from company leadership Engage with all local stakeholders and clearly communicate the program benefits and requirements Listen to the rare-disease community, recognize that there are unmet needs, and continue to evaluate program product offerings and criteria. |
| Cultural and personal                                                     | Rely on ethicists, religious leaders, and local expertise to respectfully navigate various cultural beliefs (eg, Islamic countries such as Egypt, where parents want their sons to be treated over their daughters). Partner with international patient associations when patient voice is needed and locally is not possible due to disease stigma. |
| Ensuring respect of cultural beliefs                                       | Rely on ethicists, religious leaders, and local expertise to respectfully navigate various cultural beliefs (eg, Islamic countries such as Egypt, where parents want their sons to be treated over their daughters). Partner with international patient associations when patient voice is needed and locally is not possible due to disease stigma. |
| Recognizing spectrum of disease stigma                                      | Rely on ethicists, religious leaders, and local expertise to respectfully navigate various cultural beliefs (eg, Islamic countries such as Egypt, where parents want their sons to be treated over their daughters). Partner with international patient associations when patient voice is needed and locally is not possible due to disease stigma. |

LSD, lysosomal storage disease; NGO, non-governmental organization.
Conclusion
The Sanofi Genzyme Humanitarian Program, founded to address the unmet needs of individuals with LSDs who previously had no available treatment options, represents one of the longest-running CAPs for LSD treatment. Providing sustainable global access to therapy, it has paved the way for other manufacturers of ERTs to engage in humanitarian aid, and has helped to overcome the world’s fear of “new and unknown” orphan drugs. The program has seen the successful implementation of treatment for people with rare complex LSDs, as well as improving disease awareness and helping physicians to build local capabilities. Additionally, individuals enrolled in the program have been empowered to become advocates, building patient organizations with national and global reach.

A key success has been maintaining an open-ended vision to provide treatment for rare diseases in underserved communities, which has resulted in its evolution from a charitable program for a single LSD to one that supports the provision of free treatment for five different LSDs to communities globally.

Abbreviations
AIDS: Acquired immune deficiency syndrome; CAP: Charitable access program; ERT: Enzyme replacement therapy; FD: Fabry disease; GD: Gaucher disease; HOPE: Health Opportunities for People Everywhere; JAP: Japan and Asia-Pacific; LATAM: Latin America; LSD: Lysosomal storage disorder; ME: Middle East; MPS: Mucopolysaccharidosis; NGO: Non-government organizations; PD: Pompe disease; US: United States.

Acknowledgements
A program of this magnitude would not be possible without the tireless efforts of many individuals over the past 30 years in academia, patient advocacy groups, program partners and Sanofi Genzyme employees, too numerous to list and to whom we express our deep gratitude. The authors would like to acknowledge former Genzyme founder, the late Henri Termeer for his vision and compassion in recognizing the need to create this program. The authors would also like to acknowledge the patients, physicians and program partners who were vital for the success of the program including the Gaucher Initiative US and Egypt Medical Expert Committees, Project HOPE, China Charity Federation (CCF) and China Expert Medical Committee, India Medical Advisory Board (IMAB) and the European Cerezyme Access Program (ECAP) Medical Advisory Board.

Sanofi Genzyme employees who supported the development of this manuscript:
Jasmina Ahrens, Bonnie Anderson, Nadia Daba, Medhat El-Bialy, Carmen Silvia Garcia-Cunef, Alaa Hamed, Ravinder Makkar, Jan Markind, Veronica Munoz, Elvira Ponce, and Sandeep Sahney.

The authors would also like to acknowledge the contributions of Aneela Majid, Asling O’Keeffe, Kiran Cheema, and Alex Goonesinghe, from Lucid Group Ltd., United Kingdom, for their medical writing and editorial support, funded by Sanofi Genzyme, US, for the development of this manuscript.

Authors’ contributions
All authors contributed equally to the development of this manuscript. All authors read and approved the final manuscript.

Funding
The Humanitarian Program is funded by Sanofi Genzyme. Sanofi Genzyme provided funding to Lucid Group Ltd., for support in writing and editing this manuscript under the direction of all authors.

Availability of data and materials
The datasets generated and analyzed during the current study are not publicly available due to patient privacy and confidentiality. Anonymized data can be made available upon reasonable request.

Declarations
Ethics approval and consent to participate
All patients provided informed consent to participate in the program.

Consent for publication
Consent was obtained to publish images of individuals.

Competing interests
AW has received consulting fees from Alexion, BioMarin, Chiesi, Sanofi Genzyme, Takeda, and Ultragenex; travel and congress sponsorship and fees for lectures from Alexion, Biomarin, Sanofi Genzyme, Takeda, and Ultragenex; and research grants from Alexion, BioMarin, Sanofi Genzyme, and Takeda. TCH has received research grants from Sanofi Genzyme and served on advisory boards for Sanofi Genzyme. MSvdL has received consulting fees from Amicus Therapeutics, Gilead Sciences, International Pompe Association, and Sanofi Genzyme. Her work in the Humanitarian Program never has been paid and was done on a voluntary basis. PKM has received research grant and travel support from Sanofi Genzyme. All other authors declare no competing interests.

Author details
1 Institute of Genetics and Genomics, Sir Ganga Ram Hospital, Rajinder Nagar, New Delhi 110060, India. 2 Department of Pediatrics, Faculty of Medicine, Cairo University, Cairo, Egypt. 3 Department of Pediatrics, Nutrition and Metabolic Diseases, The Children’s Memorial Health Institute, Warsaw, Poland. 4 Fabry Registry Brazil, Latin America Fabry, Gaucher, MPS I and Pompe Registries, Universidade Federal de São Paulo, São Paulo, Brazil. 5 Medical Oncology Department, Pediatric Oncology Center, Beijing Children’s Hospital, Capital Medical University, National Center for Children’s Health, Beijing, China. 6 Beijing Key Laboratory of Pediatric Hematology Oncology, Key Laboratory of Major Diseases in Children, Ministry of Education, Beijing, China. 7 International Gaucher Alliance, Dursley, UK. 8 Independent patient author, Varsseveld, the Netherlands. 9 Project HOPE (Health Opportunities for People Everywhere), Cairo, Egypt. 10 Department of Medical Genetics, Metabolism and Endocrinology, Vietnam National Children’s Hospital, Hanoi, Vietnam. 11 Department of Internal Medicine, Yale Liver Center, Yale University School of Medicine, 333 Cedar Street, PO Box 208019, New Haven, CT 06520, USA.

Received: 8 November 2021 Accepted: 30 January 2022
Published online: 04 April 2022

References
1. Global Genes. https://globalgenes.org/.
2. Global Rare Disease Commission Report. https://www.globalrarediseasecommission.com/Report/.
3. Bruni S, Losichi L, Incerti C, Gabrielli O, Coppa GV. Update on treatment of lysosomal storage diseases. Acta Myol. 2007;26(1):87–92.
4. Sun A. Lysosomal storage disease overview. Ann Transl Med. 2018;6(24):476.
5. Parenti G, Medina DL, Ballabio A. The rapidly evolving view of lysosomal storage diseases. EMBO Mol Med. 2021;13(2):e12836.
6. Mehta A, Ramaswami U, Muenzer J, Giugliani R, Ullrich K, Collin-Histed T, et al. A charitable access program for patients with lysosomal storage disorders in underserved communities worldwide. Orphanet J Rare Dis. 2021;16(1):8.
7. Sanofi Genzyme. Sanofi Genzyme Humanitarian Programs. https://www.sanofigenzyme.com/en/responsibility/humanitarian-programs.
8. Bartlett CA, McLean AN. Genzyme’s Gaucher Initiative: global risk and responsibility. Harvard Business School Case 1048 ed.
9. Molyneux DH, Asamoah-Bah A, Fenwick A, Savioli L, Hotez P. The history of the neglected tropical disease movement. Trans R Soc Trop Med Hyg. 2021;115(2):168–76.
10. Deegan PB, Cox TM. Imiglucerase in the treatment of Gaucher disease: a history and perspective. Drug Des Dev Ther. 2012;6:81–106.
11. Sanofi Genzyme. Addressing the needs of rare disease patients around the world 2019. https://www.sanofi.com/-/media/Project/One-Sanofi-Web/Websites/Global/Sanofi-COM/Home/common/docs/our-responsibility/documents-center/factsheets-2020/addressing-the-needs-of-rare-disease-patients.pdf?la=en.
12. Muranjan M. Enzyme replacement therapy for lysosomal storage disorders in India. Mol Cytogenet. 2014;7(1):29.
13. Muranjan M, Karande S. Enzyme replacement therapy in India: lessons and insights. J Postgrad Med. 2018;64(4):195–9.
14. Nampoothiri S, Yesodharan D, Bhattacherjee A, Ahamed H, Puri RD, Gupta N, et al. Fabry disease in India—a multicenter study of the clinical and mutation spectrum in 54 patients. JIMD Rep. 2020;56(1):82–94.
15. Puri RD, Setia N, Narayan V, Jagadeesh S, Nampoothiri S, Gupta N, et al. Late onset Pompe disease in India—beyond the Caucasian phenotype. Neuromuscul Disord NMD. 2021;31(5):431–41.
16. Hollak CE, vom Dahl S, Aerts JM, Belmatoug N, Bembi B, Cohen Y, et al. Force majeure: therapeutic measures in response to restricted supply of imiglucerase (Cerezyme) for patients with Gaucher disease. Blood Cells Mol Dis. 2010;44(1):41–7.
17. Hawkins J. Conscience and courage: how visionary CEO Henri Termeer built a biotech giant and pioneered the rare disease industry. New York: Cold Spring Harbor Laboratory Press; 2019.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.